Drug intelligence / Profile preview

risperidone + sertraline

Development stage
Unknown
Lead developer
Janssen Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a combination therapy consisting of risperidone and sertraline. Risperidone is an antipsychotic medication that works by balancing dopamine and serotonin levels in the brain, primarily used to treat schizophrenia, bipolar disorder, and symptoms of autism. Sertraline is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases serotonergic activity by inhibiting serotonin reuptake at presynaptic neurons, used for major depressive disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), panic disorder, and premenstrual dysphoric disorder. The combination aims to leverage the antipsychotic effects of risperidone with the antidepressant and anxiolytic effects of sertraline. Clinical studies suggest that low-dose risperidone combined with sertraline may improve psychotic symptoms and psychosocial functioning more effectively than standard doses of risperidone alone in first-episode schizophrenia patients while reducing adverse effects. Additionally, this combination has shown efficacy in treating refractory OCD with improved safety profiles compared to traditional therapies. Mechanistically: - Risperidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors. - Sertraline selectively inhibits serotonin reuptake transporters increasing synaptic serotonin concentration.

Brand names
ZoloftRisperdal
Other names
risperidone + sertraline
02

Targets

HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)DRD2 (Dopamine D2 Receptor)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on risperidone + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone + sertraline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call